EGFR and hepatocellular carcinoma: Nevertheless, this study is the first to demonstrate that ITGA3 plays a critical role in Lenvatinib resistance in HCC and that OPCs can potentially overcome this resistance by targeting the ITGA3–EGFR–AKT pathway.